Literature DB >> 17496739

Piperacillin/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.

Chin-Sheng Lin1, Chih-Jen Cheng, Chung-Hsing Chou, Shih-Hua Lin.   

Abstract

Despite popular use of piperacillin, the dire neurotoxicity associated with piperacillin still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ammonia levels but leukocytosis. Neurologic examinations showed dysarthria and bilateral Babinski sign. Computed tomography of brain and electroencephalogram were unremarkable. Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of piperacillin/tazobactam. Brain magnetic resonance imaging did not demonstrate acute infarction and organic brain lesions. Initiation of high-flux hemodialysis rapidly reversed the neurologic symptoms within 4 hours. Piperacillin-induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations. CAPD is inefficient in removing piperacillin, whereas hemodialysis can rapidly terminate the piperacillin-induced encephalopathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17496739     DOI: 10.1097/MAJ.0b013e31803195e7

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  10 in total

1.  Piperacillin/tazobactam-induced myoclonic jerks in a man with chronic renal failure.

Authors:  Bik Ling Man; Yat Pang Fu
Journal:  BMJ Case Rep       Date:  2015-05-07

2.  Neurotoxicity associated with standard doses of piperacillin in an elderly patient with renal failure.

Authors:  W-T Huang; Y-J Hsu; P-L Chu; S-H Lin
Journal:  Infection       Date:  2009-06-04       Impact factor: 3.553

Review 3.  Uremic encephalopathy in patients undergoing assisted peritoneal dialysis: a case series and literature review.

Authors:  Akane Yanai; Kiyotaka Uchiyama; Yoshitaka Ishibashi
Journal:  CEN Case Rep       Date:  2019-06-08

4.  Cefixime-induced nonconvulsive status epilepticus.

Authors:  F Anzellotti; L Ricciardi; D Monaco; F Ciccocioppo; I Borrelli; H Zhuzhuni; M Onofrj
Journal:  Neurol Sci       Date:  2011-07-01       Impact factor: 3.307

Review 5.  Neurotoxic effects associated with antibiotic use: management considerations.

Authors:  Marie F Grill; Rama K Maganti
Journal:  Br J Clin Pharmacol       Date:  2011-09       Impact factor: 4.335

6.  What Should Be Considered to Cause the Early Post-Craniotomy Seizure: Antibiotics (Cefazolin) Irrigation.

Authors:  Ji Hwan Jang; Kyung Sun Song; Jae Seung Bang; Chang Wan Oh; O-Ki Kwon; Young Seob Chung
Journal:  J Korean Neurosurg Soc       Date:  2015-11-30

7.  Myoclonic jerks secondary to piperacillin and nafcillin.

Authors:  Michael A Meyer
Journal:  Neurol Int       Date:  2014-06-16

8.  Neurologic manifestations in patients with COVID-19: A case report.

Authors:  Soheil Ebrahimpour; Zeinab Mohseni Afshar; Sima Mohseni; Jila Masrour-Roudsari; Sahar Oladzade; Masomeh Bayani; Arefeh Babazadeh
Journal:  Caspian J Intern Med       Date:  2020

9.  Citrobacter peritoneal dialysis peritonitis: rare occurrence with poor outcomes.

Authors:  Chia-Ter Chao; Szu-Ying Lee; Wei-Shun Yang; Huei-Wen Chen; Cheng-Chung Fang; Chung-Jen Yen; Chih-Kang Chiang; Kuan-Yu Hung; Jenq-Wen Huang
Journal:  Int J Med Sci       Date:  2013-07-04       Impact factor: 3.738

Review 10.  Antibiotics and the Nervous System-Which Face of Antibiotic Therapy Is Real, Dr. Jekyll (Neurotoxicity) or Mr. Hyde (Neuroprotection)?

Authors:  Magdalena Hurkacz; Lukasz Dobrek; Anna Wiela-Hojeńska
Journal:  Molecules       Date:  2021-12-09       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.